{"slideshow_credits": null, "snippet": "Marketing the antipsychotic got Johnson & Johnson a criminal record, big settlement costs and penalties \u2014 and bigger profits.", "abstract": "Nicholas Kristof Op-Ed column claims Johnson & Johnson deliberately and unethically marketed antipsychotic drug too broadly to maximize profits, which reached almost $30 billion globally, while paying just over $2 billion in settlements with consumers suffering deleterious side effects; episode is recounted in new book by journalist Steven Brill.  ", "section_name": "Opinion", "print_page": "35", "document_type": "article", "byline": {"person": [{"firstname": "Nicholas", "role": "reported", "lastname": "KRISTOF", "rank": 1, "organization": ""}], "original": "By NICHOLAS KRISTOF"}, "web_url": "http://www.nytimes.com/2015/09/17/opinion/nicholas-kristof-when-crime-pays-jjs-drug-risperdal.html", "lead_paragraph": "Marketing the antipsychotic got Johnson & Johnson a criminal record, big settlement costs and penalties \u2014 and bigger profits.", "headline": {"print_headline": "Drug Crime That Paid Billions  ", "main": "When Crime Pays: J&amp;J\u2019s Drug Risperdal", "content_kicker": "Op-Ed Columnist", "kicker": "Op-Ed Columnist"}, "_id": "55fa69f138f0d816d18468a0", "word_count": "803", "multimedia": [{"height": 126, "url": "images/2015/09/17/opinion/17kristof/17kristof-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/09/17/opinion/17kristof/17kristof-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/09/17/opinion/17kristof/17kristof-articleLarge.jpg", "legacy": {"xlarge": "images/2015/09/17/opinion/17kristof/17kristof-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/09/17/opinion/17kristof/17kristof-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2015/09/17/opinion/17kristof/17kristof-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-09-17T00:00:00Z", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"name": "organizations", "value": "Johnson & Johnson", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Advertising and Marketing", "is_major": "Y", "rank": "3"}, {"name": "persons", "value": "Brill, Steven", "is_major": "Y", "rank": "4"}, {"name": "persons", "value": "Gorsky, Alex", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Omnicare Inc", "is_major": "N", "rank": "7"}, {"name": "subject", "value": "Ethics and Official Misconduct", "is_major": "N", "rank": "8"}, {"name": "subject", "value": "Elderly", "is_major": "N", "rank": "9"}], "blog": [], "subsection_name": null, "type_of_material": "Op-Ed"}